Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05760482 |
| Other study ID # |
SelcukU002 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
September 4, 2023 |
| Est. completion date |
June 1, 2024 |
Study information
| Verified date |
June 2024 |
| Source |
Selcuk University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Psychological causes are often cited as the most important of the underlying factors for
bruxism. However, there are very few studies that can objectively demonstrate this. There are
studies that are generally based on subjective data, that is, on questionnaires that indicate
anxiety or stress. Recent studies have shown that tryptophan and its metabolites are
associated with psychological health. In this study, researchers will measure the serum
values of metabolites in the tryptophan pathway. Also, researchers will observe whether these
metabolite levels differ significantly in patients with and without bruxism.
Description:
Bruxism is a common health problem that occurs throughout life and has a prevalence of 9% to
31% among adults. This common muscle disorder, characterized by teeth grinding or clamping,
which can occur during sleep or day, is considered multifactorial with potential effects on
the central nervous system. A possible relationship between mental health and bruxism has
been investigated due to the indication of psychological factors such as anxiety and stress
at the onset of bruxism. It has been reported that when the presence of mental disorders
causes changes in the regulation of the central nervous system, they can act as a trigger
point for bruxism.
Depression and anxiety disorders are the most common mental disorders studied and are
expected to be the most common chronic condition by 2050. The emerging field of nutritional
psychiatry offers some opportunities for clinical intervention for individuals suffering from
depression and anxiety. L-tryptophan, a precursor of serotonin, is expected to contribute to
the correction of depressive and anxious moods.
The primary catabolic pathway of tryptophan is the pathway of kynurenine, which is
responsible for about 95-99% of tryptophan metabolism in the body. Tryptophan turns into
kynurenine in the kynurenine pathway and is divided into two pathways. The first forms
kynurenic acid, while the other forms 3-hydroxykynurenine (3-HK), 3-hydroxyanthranylic acid
(3-HAA), and quinolinic acid (QA), respectively. The first pathway is considered
neuroprotective, while the second pathway is known as neurotoxic.
In studies trying to explain the link between tryptophan and its metabolites and depression,
they have emphasized that depression is caused by an imbalance in the kynurenine pathway and
that the amount of quinolinic acid, which is neurotoxic, increases, while peripheral
kynurenine, which is neuroprotective, decreases. It has been shown that the neurotoxic
metabolites formed in the kynurenine itself and its pathway may be associated with depression
and anxiety. There are researchers who think that changes in these parameters and their
proportions to each other indicate different psychological states.
Changes in serum levels of these metabolites in cases of stress and anxiety have been
supported by the studies mentioned above. Although most authorities assume that bruxism is
based on psychological factors, the studies supporting them are usually anxiety and
stress-focused survey studies based on subjective data. This assumption; researchers could
not find a study comparing it with objective data. This study aims to present a possible
relationship between bruxism and tryptophan metabolites in volunteer individuals with and
without bruxism. The researchers' initial hypothesis is that "Changes in tryptophan and
catabolites play a role in the etiology of bruxism."
